Bisoprolol for congestive heart failure

@article{Rosenberg2008BisoprololFC,
  title={Bisoprolol for congestive heart failure},
  author={Jens Rosenberg and Finn Gustafsson},
  journal={Expert Opinion on Pharmacotherapy},
  year={2008},
  volume={9},
  pages={293 - 300}
}
Background: β-Blockers are a cornerstone in the treatment of systolic heart failure treatment, but not all β-blockers are effective or in this setting. Objective: To define the role of bisoprolol, a highly selective β1-antagonist in congestive heart failure due to systolic dysfunction. Methods: Using the keywords ‘bisoprolol’ and ‘heart failure’ PubMed and BIOSIS databases were searched for information regarding pharmacology and relevant randomised clinical trials. Supplementary publications… Expand
1 Citations
Application of HPLC to assess the compatibility of bisoprolol fumarate with selected excipients in mixtures by isothermal stress testing.
TLDR
Results of HPLC revealed that major degradation of bisoprolol fumarate was observed with butylated hydroxyanisole, and citric acid anhydrous, mannitol and glycerol. Expand

References

SHOWING 1-10 OF 76 REFERENCES
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
TLDR
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients. Expand
Adverse effects of -blocker therapy for patients with heart failure: A quantitative overview of ran
TLDR
Although β-blocker therapy was associated with hypotension, dizziness, and bradycardia, the absolute increases in risk were small, and overall fewer patients were withdrawn from β-blocks therapy than from placebo, which should alleviate concerns about prescribing this life-saving therapy to patients with HF. Expand
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.
TLDR
Bisoprolol prevents major cardiovascular events in patients with CHF with a high benefit-to-risk ratio and can be recommended for these patients. Expand
Tolerability of β-Blocker Initiation and Titration with Bisoprolol and Carvedilol in Congestive Heart Failure – A Randomized Comparison
TLDR
Almost twice the number of unselected patients with systolic CHF attending a heart failure clinic focusing on systematic medical titration were intolerant to BB treatment and only a minority reached target dose treatment, and no parameter predicts tolerability. Expand
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
TLDR
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor. Expand
Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III
TLDR
The results indicate that it may be as safe and efficacious to initiate treatment for CHF with bisoprolol as with enalapril. Expand
Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II).
TLDR
Bisoprolol reduces mortality in CHF patients at all tolerated dose levels and its withdrawal increases the risk of mortality and efforts should be made to maintain bisoproll therapy based on the individual patient's tolerability. Expand
A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.
TLDR
These results confirm previous trials evidence that a progressively increasing dose of beta-blocker in severe heart failure confers functional benefit, and suggest that benefit frombeta-blockade therapy was greater for those with nonischemic cardiomyopathy. Expand
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
TLDR
Although beta-blocker therapy was associated with hypotension, dizziness, and bradycardia, the absolute increases in risk were small, and overall fewer patients were withdrawn from beta-blocks therapy than from placebo, which should alleviate concerns about prescribing this life-saving therapy to patients with HF. Expand
Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure
TLDR
Analysis in high‐risk subgroups of patients taking part in CIBIS II have been performed to investigate the effect of bisoprolol in elderly patients, in patients with type 2 diabetes, with renal failure, NYHA functional class IV or concomitantly treated with digitalis, aldosterone antagonists or amiodarone. Expand
...
1
2
3
4
5
...